Identification of anticoagulants in a sample
AssigneePentapharm AG
InventorsAbel Ferrandez, Anne Brisset
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a novel method of determining inhibitors of proteolytically active coagulation factors, referred to herein as anticoagulants, in a sample, in particular the qualitative detection of direct thrombin and factor Xa inhibitors in a sample. The method of the present invention allows a qualitative determination of the nature anticoagulants present in a sample. This can be achieved with only one coagulation-based test. The method can be used in a test kit, including a point-of-care (POC) system.
Claims17
A method of analyzing a patient sample comprising:
- (a) measuring clotting time in the sample via standard prothrombinase-induced clotting time (PiCT) comprising steps in a sequential order:
- adding to the sample a defined amount of PiCT activator, incubating the sample with the activator at 37° C., adding a start reagent, and measuring time to clot;
- and
- (b) measuring clotting time in the sample via inverted PiCT comprising steps in a subsequent order:
- adding to the sample the start reagent, incubating the sample with the start reagent at 37° C. for a time period from 60 seconds to 160 seconds, adding a PiCT activator, and measuring time to clot, wherein the patient sample is blood or plasma.
A method of identifying an anticoagulant drug in a patient sample comprising:
- (a) measuring clotting time in the sample via standard prothrombinase-induced clotting time (PiCT) comprising steps in a sequential order:
- adding to the sample a defined amount of PiCT activator, incubating the sample with the activator at 37° C., adding a start reagent, and measuring time to clot;
- and
- (b) measuring clotting time in the sample via inverted PiCT comprising steps in a subsequent order:
- adding to the sample the start reagent, incubating the sample with the start reagent at 37° C. for a time period from 60 seconds to 160 seconds, adding a PiCT activator, and measuring time to clot, wherein the patient sample is blood or plasma.
Dependencies are inferred from the claim text.